Nugc3

We used GC cell lines, which were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) as follows: MKN1, MKN45, MKN74, NUGC2, NUGC3, NUGC4, and SC-6-JCK. The GC cell lines AGS, KATOIII, and N87 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The human intestinal epithelial cell line FHs74Int (ATCC) served as a nontumorigenic control. Primary GC tissues and corresponding noncancerous mucosal tissues were collected from 200 patients who underwent gastrectomy at Nagoya University Hospital between 2001 and 2014. None of the patients underwent preoperative chemotherapy.
The methods were carried out in accordance with relevant guidelines. The study protocol was approved by the Medical Ethics Committee of the Nagoya University Hospital, protocol No. 2014–0043. Informed consent was obtained from all patients. Written informed consent for the use of clinical samples and data, as required by the Institutional Review Board, was obtained from all patients.

GC cell lines, the differentiated type (AGS, IM95, MKN1, MKN7, MKN74 and N87) and the undifferentiated type (GCIY, KATO-III, MKN45, NUGC2, NUGC3, NUGC4, OCUM1 and SC-6-JCK), were obtained from the Japanese Collection of Research Bio Resources Cell Bank (Osaka, Japan) or the American Type Culture Collection (ATCC, Manassas, VA, USA). A control, non-tumorigenic epithelial cell line (FHs 74) was purchased from the ATCC. The cells were cultured at 37 °C in RPMI medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% foetal bovine serum in an atmosphere containing 5% CO₂. All cell lines were authenticated using the short tandem repeat PCR method by the Japanese Collection of Research Bio Resources Cell Bank before the study commenced.

Six human gastric cancer cell lines (MKN7, MNK74, MNK45, NUGC3, NUGC4, and KATOIII) were obtained from the JCRB Cell Bank (Osaka, Japan) and the RIKEN Bioresource Center (Tsukuba, Japan). All cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37 °C in a humidified atmosphere containing 5% CO₂.

The Ca9-22, HEL, NUGC-3, and RPMI8226 cell lines were obtained from the Japanese Collection of Research Bioresources. The 786-O, CFPAC-1, DU145, HCC1599, HCC1806, HCC38, HCT116, HL-60, K-562, MSTO-211H, MV-4-11, NCI-H460, NCI-H2170, and THP-1 cell lines were obtained from the ATCC. The A2780, COLO 792, and DOK cell lines were obtained from the European Collection of Authenticated Cell Cultures. The A549, A673, BHL-89, and MCF-7 cell lines were obtained from DS Pharma Biomedical Co., Ltd. Short-tandem repeat-based DNA profiling was used to reauthenticate cell lines. All cell lines were tested for mycoplasma contamination.

The GC cell lines GCIY, IM95, MKN1, MKN7, MKN45, MKN74, NUGC2, NUGC3, NUGC4, OCUM-1, and SC-6-JCK were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB, Osaka, Japan). AGS, KATOIII, and N87 GC cell lines and a nontumorigenic epithelial cell line (FHs74) were acquired from the American Type Culture Collection (Manassas, VA, USA). Three hundred pairs of surgically resected GC and adjacent noncancerous tissues were obtained from patients who underwent gastrectomy. A freely available integrated dataset (n = 1065 GC patients) was accessed at http://kmplot.com/analysis/ [13 (link)].

The human gastric cancer cell lines MKN1 (RRID, CVCL_1415), MKN74 (CVCL_2791), MKN45 (CVCL_0434), and NUGC3 (CVCL_1612), as well as HeLa cervical carcinoma cells (CVCL_0030), were obtained from the JCRB cell bank. The human gastric cancer cell lines SNU1 (CVCL_0099), Hs746T (CVCL_0333), and NCI‐N87 (CVCL_1603) were from American Type Culture Collection and SNU216 (CVCL_3946) was from the Korean Cell Line Bank. The cells were maintained under a humidified atmosphere of 5% CO₂ at 37°C in RPMI 1640 medium (Sigma‐Aldrich) supplemented with 10% heat‐inactivated fetal bovine serum (FBS) (Biowest) and 1% penicillin‐streptomycin‐amphotericin B (Wako). Cells were tested for mycoplasma contamination using MycoAlert (LT07, Lonza) and were confirmed negative. Eribulin was obtained from Eisai Co. Ltd and Oxaliplatin from Yakult. MORAb‐202 and farletuzumab were provided by Eisai Co. Ltd. MG132 was obtained from Funakoshi.